HRMY Stock Overview
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Harmony Biosciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.79 |
| 52 Week High | US$41.61 |
| 52 Week Low | US$27.97 |
| Beta | 0.77 |
| 11 Month Change | -6.18% |
| 3 Month Change | -8.94% |
| 1 Year Change | 15.05% |
| 33 Year Change | -14.59% |
| 5 Year Change | n/a |
| Change since IPO | -11.40% |
Recent News & Updates
Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points
Nov 11Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 31
Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?
Oct 30Recent updates
Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points
Nov 11Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 31Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?
Oct 30Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Sep 25Harmony Biosciences: Advancing An Expanded Pipeline
Aug 15Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Jul 15Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Jun 07Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 03These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Apr 04Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Feb 09Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Mar 21Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?
Dec 01Harmony Biosciences: In Harmony
Sep 23We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease
Aug 05Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M
Aug 02Harmony Biosciences: Steady Revenue Generator Looking For A Future
May 26Shareholder Returns
| HRMY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.1% | -3.8% | -1.0% |
| 1Y | 15.1% | 9.8% | 30.3% |
Return vs Industry: HRMY exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: HRMY underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| HRMY volatility | |
|---|---|
| HRMY Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HRMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HRMY's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 246 | Jeffrey Dayno | www.harmonybiosciences.com |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons.
Harmony Biosciences Holdings, Inc. Fundamentals Summary
| HRMY fundamental statistics | |
|---|---|
| Market cap | US$1.85b |
| Earnings (TTM) | US$122.63m |
| Revenue (TTM) | US$681.88m |
15.3x
P/E Ratio2.7x
P/S RatioIs HRMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HRMY income statement (TTM) | |
|---|---|
| Revenue | US$681.88m |
| Cost of Revenue | US$145.56m |
| Gross Profit | US$536.32m |
| Other Expenses | US$413.70m |
| Earnings | US$122.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.15 |
| Gross Margin | 78.65% |
| Net Profit Margin | 17.98% |
| Debt/Equity Ratio | 30.6% |
How did HRMY perform over the long term?
See historical performance and comparison